Literature DB >> 23406785

A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.

Judith M Ertle1, Dominik Heider, Marc Wichert, Benedikt Keller, Robert Kueper, Philip Hilgard, Guido Gerken, Joerg F Schlaak.   

Abstract

BACKGROUND AND AIM: The incidence of hepatocellular carcinoma (HCC) is increasing in western countries. Despite its low sensitivity, the diagnosis of HCC still depends on detection of α-fetoprotein (AFP). Therefore, the aim of this study was to evaluate the combined analysis of AFP and des-γ-carboxy prothrombin (DCP) in a European cohort.
METHODS: We performed a single-center study (164 HCC/422 controls), in which the serum concentrations of AFP and DCP were determined.
RESULTS: AFP and DCP were elevated in HCC patients compared to controls (p < 0.0001). By combination of AFP and DCP, the sensitivity was improved from 28.7% for AFP (cutoff 400 ng/ml; AFP at cutoff 10 ng/ml: 54.9%) to 78.0% using cutoffs of 10 ng/ml for AFP and 5 ng/ml for DCP (DCP alone, cutoff 5 ng/ml: 63.4%). Among early-stage patients, the sensitivity increased from 20% for AFP (cutoff 400 ng/ml; AFP at cutoff 10 ng/ml: 38%) to 55% in combination (DCP alone, cutoff 5 ng/ml: 47%). The area under the curve (AUC) for AFP and DCP was similar (AFP: 0.88; DCP: 0.87; combined: 0.91). Among non-cirrhotic patients, DCP (AUC: 0.93) showed a better performance than AFP (AUC: 0.84). Especially patients with non-alcoholic steatohepatitis had a high percentage of DCP-positive tumors.
CONCLUSION: The data suggest that AFP alone is not sufficient for the serological diagnosis of HCC in European patients, while a combination of AFP and DCP can increase the sensitivity even in early-stage patients.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406785     DOI: 10.1159/000346080

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  50 in total

Review 1.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

2.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 3.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

4.  Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.

Authors:  Ivan Gentile; Antonio Riccardo Buonomo; Riccardo Scotto; Emanuela Zappulo; Canio Carriero; Mauro Piccirillo; Francesco Izzo; Marianna Rizzo; Dionigio Cerasuolo; Guglielmo Borgia; Ernesta Cavalcanti
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 5.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.

Authors:  Hao Wu; Yan Liu; Xiao-Wei Jiang; Wen-Fang Li; Gang Guo; Jian-Ping Gong; Xiong Ding
Journal:  Tumour Biol       Date:  2016-07-28

7.  Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.

Authors:  Satoshi Shakado; Shotaro Sakisaka; Kazuaki Chayama; Takeshi Okanoue; Joji Toyoda; Namiki Izumi; Akihiro Matsumoto; Tetsuo Takehara; Akio Ido; Yoichi Hiasa; Kentaro Yoshioka; Hideyuki Nomura; Yoshiyuki Ueno; Masataka Seike; Hiromitsu Kumada
Journal:  World J Hepatol       Date:  2015-11-28

8.  PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.

Authors:  Sarka Svobodova; Marie Karlikova; Ondrej Topolcan; Ladislav Pecen; Martina Pestova; Otto Kott; Vladislav Treska; David Slouka; Radek Kucera
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 9.  Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment.

Authors:  Kerstin Schütte; Christian Schulz; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2014-05-09

10.  Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma.

Authors:  Biqiong Ren; Guoying Zou; Fei Xu; Yiran Huang; Guofeng Xu; Junyu He; Yong Li; Haowen Zhu; Ping Yu
Journal:  Oncol Lett       Date:  2017-10-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.